Publications

2026 cardiometabolic

Use of Inhaled Insulin with Automated Insulin Delivery Systems

Diabetes Technology & Therapeutics

February 1, 2026, Volume 28 Issue 1 Pages 38S – 42S

2026 cardiometabolic

Potential Role of Inhaled Insulin in the Management of Gestational Diabetes Mellitus and Pediatric Type 1 Diabetes

Diabetes Technology & Therapeutics

February 1, 2026, Volume 28 Issue 1 Pages 43S – 54S

2026 cardiometabolic

Case Reports: Practical Use of Pulmonary Inhaled (Technosphere) Insulin in Type 1 Diabetes, Type 2 Diabetes, and Pregnancy

Diabetes Technology & Therapeutics

February 1, 2026, Volume 28 Issue 1 Pages 55S – 63S

2026 cardiometabolic

The Potential of Inhaled Insulin Therapy in Overcoming Treatment Barriers in People with Insulin-Treated Diabetes.

Diabetes Technology & Therapeutics

February 1, 2026, Volume 28 Issue 1 Pages 64S – 69S

2026 cardiometabolic

Overcoming Therapeutic Inertia with Inhaled Insulin Therapy

Diabetes Technology & Therapeutics

February 1, 2026, Volume 28 Issue 1 Pages 70S – 76S

2026 cardiometabolic

Safety of Inhaled Insulin in Adults with Diabetes

Diabetes Technology & Therapeutics

January 23, 2026, Volume 28 Issue 3 Pages 191-192

2026 cardiometabolic

Real-World Incidence of Lung Malignancy and Chronic Obstructive Pulmonary Disease with Inhaled Insulin in People with Diabetes

Diabetes Technology & Therapeutics

January 23, 2026, Volume 28 Issue 3 Pages 201-205

2026 cardiometabolic

A Real-World Data Assessment of Pulmonary Toxicity of Inhaled Insulin for Diabetes

Diabetes Technology & Therapeutics

January 21, 2026, Volume 28 Issue 6 Pages 527-531

2026 orphan lung

Safety and Pharmacokinetic Data for Inhaled Administration of Nintedanib Dry Powder Inhalation for Treatment of Pulmonary Fibrotic Diseases

Journal of Aerosol Medicine and Pulmonary Drug Delivery

January 13, 2026 Volume 39, Issue 4, Pages 185-197

2025 cardiometabolic

INHALE-1: A Multicenter Randomized Trial of Inhaled Technosphere Insulin in Children With Type 1 Diabetes

Diabetes Care

November 12, 2025, Volume 49 Issue 1 Pages 1-9

2025 cardiometabolic

Replacing or Supplementing Automated Insulin Delivery With Inhaled Insulin: A 90-Day Randomized Controlled Trial

Journal of Diabetes Science and Technology

Published Online: November 11, 2025

2025 cardiometabolic

Breathing Fresh Life Into Inhaled Insulin: Innovative Applications for an Underutilized Therapy

ADCES in Practice

November 5, 2025, Volume 14 Issue 1 Pages 34-39

Use of Inhaled Insulin with Automated Insulin Delivery Systems

Potential Role of Inhaled Insulin in the Management of Gestational Diabetes Mellitus and Pediatric Type 1 Diabetes

Case Reports: Practical Use of Pulmonary Inhaled (Technosphere) Insulin in Type 1 Diabetes, Type 2 Diabetes, and Pregnancy

The Potential of Inhaled Insulin Therapy in Overcoming Treatment Barriers in People with Insulin-Treated Diabetes.

Overcoming Therapeutic Inertia with Inhaled Insulin Therapy

Safety of Inhaled Insulin in Adults with Diabetes

Real-World Incidence of Lung Malignancy and Chronic Obstructive Pulmonary Disease with Inhaled Insulin in People with Diabetes

A Real-World Data Assessment of Pulmonary Toxicity of Inhaled Insulin for Diabetes

Safety and Pharmacokinetic Data for Inhaled Administration of Nintedanib Dry Powder Inhalation for Treatment of Pulmonary Fibrotic Diseases

INHALE-1: A Multicenter Randomized Trial of Inhaled Technosphere Insulin in Children With Type 1 Diabetes

Replacing or Supplementing Automated Insulin Delivery With Inhaled Insulin: A 90-Day Randomized Controlled Trial

Breathing Fresh Life Into Inhaled Insulin: Innovative Applications for an Underutilized Therapy

Expanding Patient Choice in Diabetes Care: Reducing Access Barriers to Inhaled Insulin

Experiences With Inhaled Insulin in a Real-World Sample of Adults With Type 1 Diabetes in the T1D Exchange Registry

Inhaled Insulin Dosing in a Randomized Trial in Adults With Type 1 Diabetes

Inhaled Technosphere Insulin Reduces Postmeal Glucose Excursion in Youth Living with Type 1 Diabetes

Inhaled Technosphere Insulin in Children with Diabetes: The INHALE-1 Extension Study

Role of Ultra-Rapid Acting Insulin in Managing Diabetes

30 Years of Developing Inhaled Insulin

Dosing Afrezza: It's Not that Complicated

Unmet Needs in Insulin-Treated Diabetes Management

Pulmonary Safety and Clinical Considerations for Inhaled Insulin: A Comprehensive Review

Impact of Inhaled Insulin Therapy on Hypoglycemia

Potential Applications of Inhaled Insulin in Diabetic Ketoacidosis Prevention and During Exercise: Two Case Presentations

Safety and Pharmacokinetic Data for Inhaled Administration of Nintedanib Dry Powder Inhalation for Treatment of Pulmonary Fibrotic Diseases

Preclinical Studies of Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease

Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease

Inhaled, Nebulized Clofazimine for the Treatment of Pulmonary Nontuberculous Mycobacteria Disease Offers the Prospect of Convenient Dosing and Prolonged Activity

Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection

Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections

Now FDA Approved:
Furoscix ReadyFlow™

(furosemide injection)

Publications

Use of Inhaled Insulin with Automated Insulin Delivery Systems

Potential Role of Inhaled Insulin in the Management of Gestational Diabetes Mellitus and Pediatric Type 1 Diabetes

Case Reports: Practical Use of Pulmonary Inhaled (Technosphere) Insulin in Type 1 Diabetes, Type 2 Diabetes, and Pregnancy

The Potential of Inhaled Insulin Therapy in Overcoming Treatment Barriers in People with Insulin-Treated Diabetes.

Overcoming Therapeutic Inertia with Inhaled Insulin Therapy

Safety of Inhaled Insulin in Adults with Diabetes

Real-World Incidence of Lung Malignancy and Chronic Obstructive Pulmonary Disease with Inhaled Insulin in People with Diabetes

A Real-World Data Assessment of Pulmonary Toxicity of Inhaled Insulin for Diabetes

Safety and Pharmacokinetic Data for Inhaled Administration of Nintedanib Dry Powder Inhalation for Treatment of Pulmonary Fibrotic Diseases

INHALE-1: A Multicenter Randomized Trial of Inhaled Technosphere Insulin in Children With Type 1 Diabetes

Replacing or Supplementing Automated Insulin Delivery With Inhaled Insulin: A 90-Day Randomized Controlled Trial

Breathing Fresh Life Into Inhaled Insulin: Innovative Applications for an Underutilized Therapy

Expanding Patient Choice in Diabetes Care: Reducing Access Barriers to Inhaled Insulin

Experiences With Inhaled Insulin in a Real-World Sample of Adults With Type 1 Diabetes in the T1D Exchange Registry

Inhaled Insulin Dosing in a Randomized Trial in Adults With Type 1 Diabetes

Inhaled Technosphere Insulin Reduces Postmeal Glucose Excursion in Youth Living with Type 1 Diabetes

Inhaled Technosphere Insulin in Children with Diabetes: The INHALE-1 Extension Study

Role of Ultra-Rapid Acting Insulin in Managing Diabetes

30 Years of Developing Inhaled Insulin

Dosing Afrezza: It's Not that Complicated

Unmet Needs in Insulin-Treated Diabetes Management

Pulmonary Safety and Clinical Considerations for Inhaled Insulin: A Comprehensive Review

Impact of Inhaled Insulin Therapy on Hypoglycemia

Potential Applications of Inhaled Insulin in Diabetic Ketoacidosis Prevention and During Exercise: Two Case Presentations

Safety and Pharmacokinetic Data for Inhaled Administration of Nintedanib Dry Powder Inhalation for Treatment of Pulmonary Fibrotic Diseases

Preclinical Studies of Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease

Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease

Inhaled, Nebulized Clofazimine for the Treatment of Pulmonary Nontuberculous Mycobacteria Disease Offers the Prospect of Convenient Dosing and Prolonged Activity

Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection

Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections

Now FDA Approved: Furoscix ReadyFlow™

(furosemide injection)

Now FDA Approved:
Furoscix ReadyFlow™